This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

CAPT. THOMAS W. SHEEHY, MC; CAPT. JAMES W. RANSONE, MC

AMA Arch Intern Med. 1957;100(1):85-89.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In 1950, demecolcine (Colcemid) was isolated from Colchicum autumnale.¹ In 1953, Moeschlin et al.² reported its use and beneficial effects in a case of chronic granulocytic leukemia, with a fall in white cell count, a decrease in splenomegaly, and increased erythroid elements in the marrow. The doses ranged from 3 to 8 mg. daily.

In 1955, Leonard and Wilkinson³ confirmed Moeschlin's findings in eight cases of chronic granulocytic leukemia in which a dosage of 3 to 10 mg. daily for four to nine months was used. The toxic effects were mild and consisted of some loss of scalp hair, erythema of the scrotum, and, in one case, congestion and erythema of the pharynx.

Our report is prompted by the sudden and severe side-effects in one patient with follicular lymphoma and in another patient with chronic granulocytic leukemia who were both given demecolcine.

Report of Cases

CASE 1. . . . [Full Text PDF of this Article]

Author Affiliations
U. S. Army

Department of Hematology, Walter Reed Army Institute of Research (Capt. Sheehy), and Department of Medicine, Walter Reed Army Hospital (Capt. Ransone), WRAMC, Washington 12, D. C.

Footnotes
Submitted for publication Jan. 16, 1957.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?